Insulin Resistance and Atherosclerosis

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 575-587

  Raghavan, Vasudevan A ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Insulin resistance

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIVER; MACROPHAGE; NONHUMAN; OBESITY; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; OBESITY; OXIDATIVE STRESS;

EID: 84866614602     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.014     Document Type: Review

References (98)

1. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(3):193-205.
2. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 35(Suppl 1):S64-S71.
3. Moller D.E., Flier J.S. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991, 325(13):938-948.
4. Seino S., Seino M., Nishi S., et al. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A 1989, 86(1):114-118.
5. Cheatham B., Kahn C.R. Insulin action and the insulin signaling network. Endocr Rev 1995, 16(2):117-142.
6. White M.F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998, 182(1-2):3-11.
7. Shepherd P.R., Kahn B.B. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 1999, 341(4):248-257.
8. Shulman G.I. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999, 84(1A):3J-10J.
9. Sasaoka T., Rose D.W., Jhun B.H., et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 1994, 269(18):13689-13694.
10. Sasaoka T., Ishiki M., Sawa T., et al. Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 1996, 137(10):4427-4434.
11. Jiang Z.Y., Lin Y.W., Clemont A., et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104(4):447-457.
12. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105(3):311-320.
13. Zecchin H.G., Bezerra R.M., Carvalheira J.B., et al. Insulin signalling pathways in aorta and muscle from two animal models of insulin resistance-the obese middle-aged and the spontaneously hypertensive rats. Diabetologia 2003, 46(4):479-491.
14. Law R.E., Meehan W.P., Xi X.P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996, 98(8):1897-1905.
15. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976, 295(7):369-377.
16. Libby P., Hansson G.K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991, 64(1):5-15.
17. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6(7):508-519.
18. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12(3):204-212.
19. Yla-Herttuala S., Bentzon J.F., Daemen M., et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost 2011, 106(1):1-19.
20. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17(11):1410-1422.
21. Lusis A.J. Atherosclerosis. Nature 2000, 407(6801):233-241.
22. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010, 10(1):36-46.
23. Henry R.R. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124(1 Pt 2):97-103.
24. Krauss R.M. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med 1998, 105(1A):58S-62S.
25. Krauss R.M. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998, 81(4A):13B-17B.
26. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43(9):1363-1379.
27. McNamara J.R., Jenner J.L., Li Z., et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992, 12(11):1284-1290.
28. McNamara J.R., Campos H., Ordovas J.M., et al. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study. Arteriosclerosis 1987, 7(5):483-490.
29. Krauss R.M., Williams P.T., Lindgren F.T., et al. Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men. Arteriosclerosis 1988, 8(2):155-162.
30. Blanche P.J., Gong E.L., Forte T.M., et al. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981, 665(3):408-419.
31. Hopkins G.J., Barter P.J. Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 1986, 27(12):1265-1277.
32. Campos H., Arnold K.S., Balestra M.E., et al. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 1996, 16(6):794-801.
33. Pascot A., Lemieux I., Prud'homme D., et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001, 42(12):2007-2014.
34. Bjornheden T., Babyi A., Bondjers G., et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996, 123(1-2):43-56.
35. Anber V., Griffin B.A., McConnell M., et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996, 124(2):261-271.
36. Chait A., Brazg R.L., Tribble D.L., et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94(4):350-356.
37. de Graaf J., Hak-Lemmers H.L., Hectors M.P., et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11(2):298-306.
38. Tribble D.L., Holl L.G., Wood P.D., et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992, 93(3):189-199.
39. Kannel W.B., McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2(2):120-126.
40. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316(7134):823-828.
41. Prince C.T., Becker D.J., Costacou T., et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 2007, 50(11):2280-2288.
42. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47(6):859-866.
43. Derubertis F.R., Craven P.A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994, 43(1):1-8.
44. Xia P., Inoguchi T., Kern T.S., et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994, 43(9):1122-1129.
45. Koya D., Jirousek M.R., Lin Y.W., et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997, 100(1):115-126.
46. Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272(5262):728-731.
47. Kuboki K., Jiang Z.Y., Takahara N., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000, 101(6):676-681.
48. Studer R.K., Craven P.A., DeRubertis F.R. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993, 42(1):118-126.
49. Feener E.P., Xia P., Inoguchi T., et al. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib Nephrol 1996, 118:180-187.
50. Koya D., Haneda M., Nakagawa H., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14(3):439-447.
51. Piga R., Naito Y., Kokura S., et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007, 193(2):328-334.
52. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994, 269(13):9889-9897.
53. Dasu M.R., Devaraj S., Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007, 293(1):E337-E346.
54. Kawamura M., Heinecke J.W., Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994, 94(2):771-778.
55. Miyazaki A., Nakayama H., Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002, 12(6):258-262.
56. Ohgami N., Miyazaki A., Sakai M., et al. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 2003, 10(1):1-6.
57. Roytblat L., Rachinsky M., Fisher A., et al. Raised interleukin-6 levels in obese patients. Obes Res 2000, 8(9):673-675.
58. Straczkowski M., Dzienis-Straczkowska S., Stepien A., et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002, 87(10):4602-4606.
59. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994, 43(11):1271-1278.
60. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100(12):7265-7270.
61. Hotamisligil G.S., Arner P., Caro J.F., et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95(5):2409-2415.
62. Visser M., Bouter L.M., McQuillan G.M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282(22):2131-2135.
63. de Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett 2008, 582(1):97-105.
64. Kim F., Tysseling K.A., Rice J., et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005, 25(5):989-994.
65. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
66. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271(5249):665-668.
67. Uysal K.T., Wiesbrock S.M., Marino M.W., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389(6651):610-614.
68. Stephens J.M., Lee J., Pilch P.F. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997, 272(2):971-976.
69. Ruan H., Hacohen N., Golub T.R., et al. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002, 51(5):1319-1336.
70. Hirosumi J., Tuncman G., Chang L., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
71. Tuncman G., Hirosumi J., Solinas G., et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 2006, 103(28):10741-10746.
72. Williamson R.T. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901, 1(2100):760-762.
73. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396(6706):77-80.
74. Kim J.K., Kim Y.J., Fillmore J.J., et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108(3):437-446.
75. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001, 293(5535):1673-1677.
76. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11(2):183-190.
77. Sugita H., Fujimoto M., Yasukawa T., et al. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 2005, 280(14):14203-14211.
78. Yasukawa T., Tokunaga E., Ota H., et al. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J Biol Chem 2005, 280(9):7511-7518.
79. Perreault M., Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001, 7(10):1138-1143.
80. Carvalho-Filho M.A., Ueno M., Carvalheira J.B., et al. Targeted disruption of iNOS prevents LPS-induced S-nitrosylation of IRbeta/IRS-1 and Akt and insulin resistance in muscle of mice. Am J Physiol Endocrinol Metab 2006, 291(3):E476-E482.
81. Carvalho-Filho M.A., Ueno M., Hirabara S.M., et al. S-nitrosylation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 2005, 54(4):959-967.
82. Schottelius A.J., Mayo M.W., Sartor R.B., et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999, 274(45):31868-31874.
83. van Exel E., Gussekloo J., de Craen A.J., et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002, 51(4):1088-1092.
84. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117(1):175-184.
85. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55(2):241-269.
86. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112(12):1796-1808.
87. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112(12):1821-1830.
88. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11(2):191-198.
89. Kurihara T., Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem 1996, 271(20):11603-11607.
90. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116(1):115-124.
91. Kamei N., Tobe K., Suzuki R., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281(36):26602-26614.
92. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116(6):1494-1505.
93. Inouye K.E., Shi H., Howard J.K., et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007, 56(9):2242-2250.
94. Rutkowski D.T., Kaufman R.J. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci 2007, 32(10):469-476.
95. Özcan U., Cao Q., Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
96. Özcan U., Yilmaz E., Özcan L., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313(5790):1137-1140.
97. Ou H.Y., Wu H.T., Hung H.C., et al. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 2012, 153(7):2974-2984.
98. Achard C.S., Laybutt D.R. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance. Endocrinology 2012, 153(5):2164-2177.